相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues
Ashwini Balakrishnan et al.
CLINICAL CANCER RESEARCH (2017)
Mining Naive Rabbit Antibody Repertoires by Phage Display for Monoclonal Antibodies of Therapeutic Utility
Haiyong Peng et al.
JOURNAL OF MOLECULAR BIOLOGY (2017)
The making of bispecific antibodies
Ulrich Brinkmann et al.
MABS (2017)
Therapeutic T cell engineering
Michel Sadelain et al.
NATURE (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Affibody Molecules in Biotechnological and Medical Applications
Stefan Stahl et al.
TRENDS IN BIOTECHNOLOGY (2017)
An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors
Satyen Harish Gohil et al.
ONCOIMMUNOLOGY (2017)
Camelid and shark single domain antibodies: structural features and therapeutic potential
Doreen Koenning et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2017)
New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management
Frank Kroschinsky et al.
CRITICAL CARE (2017)
Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing
Ji Li et al.
CANCER CELL (2017)
Pharmacokinetic properties of IgG and various Fc fusion proteins in mice
Felix Unverdorben et al.
MABS (2016)
Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma
A. Viardot et al.
BLOOD (2016)
High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia
Bing Cui et al.
BLOOD (2016)
Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications
Min Zhu et al.
CLINICAL PHARMACOKINETICS (2016)
Targeting Stereotyped B Cell Receptors from Chronic Lymphocytic Leukemia Patients with Synthetic Antigen Surrogates
Mohosin Sarkar et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Chemically Programmed Bispecific Antibodies in Diabody Format
Even Walseng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Transpo-mAb display: Transposition-mediated B cell display and functional screening of full-length IgG antibody libraries
Lorenz Waldmeier et al.
MABS (2016)
Structure of the Dual-Mode Wnt Regulator Kremen1 and Insight into Ternary Complex Formation with LRP6 and Dickkopf
Matthias Zebisch et al.
STRUCTURE (2016)
Advances in Therapeutic Fc engineering - Modulation of igG-Associated effector Functions and Serum Half-life
Abhishek Saxena et al.
FRONTIERS IN IMMUNOLOGY (2016)
Engineered T cells: the promise and challenges of cancer immunotherapy
Andrew D. Fesnak et al.
NATURE REVIEWS CANCER (2016)
Origins of the cytolytic synapse
Maike de la Roche et al.
NATURE REVIEWS IMMUNOLOGY (2016)
Designed Ankyrin Repeat Proteins (DARPins): Binding Proteins for Research, Diagnostics, and Therapy
Andreas Plueckthun
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 55 (2015)
Non-immunoglobulin scaffolds: a focus on their targets
Katja Skrlec et al.
TRENDS IN BIOTECHNOLOGY (2015)
Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor-Modified T Cells
Carolina Berger et al.
CANCER IMMUNOLOGY RESEARCH (2015)
The receptor tyrosine kinase ROR1-An oncofetal antigen for targeted cancer therapy
Mohammad Hojjat-Farsangi et al.
SEMINARS IN CANCER BIOLOGY (2014)
Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells
Michael Hudecek et al.
CLINICAL CANCER RESEARCH (2013)
Targeting T cells to tumor cells using bispecific antibodies
Stanley R. Frankel et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2013)
Generation and Comparative Characterization of Glycosylated and Aglycosylated Human IgG1 Antibodies
Dmitrij Hristodorov et al.
MOLECULAR BIOTECHNOLOGY (2013)
Targeting malignant B cells with an immunotoxin against ROR1
Sivasubramanian Baskar et al.
MABS (2012)
Restricted Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Pediatric B-Lineage Acute Lymphoblastic Leukemia Suggests Targetability with Therapeutic Monoclonal Antibodies
Hema Dave et al.
PLOS ONE (2012)
iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM
T. Geoff G. Battye et al.
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2011)
ROR1 expression is not a unique marker of CLL
Gabor Barna et al.
HEMATOLOGICAL ONCOLOGY (2011)
Therapeutic Potential and Challenges of Targeting Receptor Tyrosine Kinase ROR1 with Monoclonal Antibodies in B-Cell Malignancies
Jiahui Yang et al.
PLOS ONE (2011)
MolProbity: all-atom structure validation for macromolecular crystallography
Vincent B. Chen et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2010)
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Paul D. Adams et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2010)
The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor
Michael Hudecek et al.
BLOOD (2010)
Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen
Claudia Bluemel et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia
Sivasubramanian Baskar et al.
CLINICAL CANCER RESEARCH (2008)
Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy
Amir H. DaneshManesh et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal,antigen and receptor for Wnt5a
Tetsuya Fukuda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
BALBES: a molecular-replacement pipeline
Fei Long et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2008)
Inference of macromolecular assemblies from crystalline state
Evgeny Krissinel et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
The 1.4 Å crystal structure of the human oxidized low density lipoprotein receptor Lox-1
H Park et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Cancer immunotherapy: A treatment for the masses
JN Blattman et al.
SCIENCE (2004)
Coot:: model-building tools for molecular graphics
P Emsley et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2004)
Crystal structure of a human CD-ε/δ dimer in complex with a UCHT1 single-chain antibody fragment
KL Arnett et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Crystal structure of the human T cell receptor CD3εγ heterodimer complexed to the therapeutic mAb OKT3
L Kjer-Nielsen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy
C Rader et al.
JOURNAL OF MOLECULAR BIOLOGY (2003)
High-resolution crystal structure of apolipoprotein(a) kringle IV type 7: Insights into ligand binding
QL Ye et al.
PROTEIN SCIENCE (2001)